Positive Study Results As a common medication prescribed for post-menopausal women to treat and prevent osteoporosis, Raloxifene has now been recognized as a potential viable treatment for both breast and liver cancer. A recently released study, conducted at Oregon State University, demonstrated powerful data touting the use of Raloxifene to treat triple-negative breast cancer (TNBC)[…]
Raloxifene Treatment for Breast Cancer and Liver Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, OTC and Compounding Product, TEVA API Tags: breast cancer Mar 19, 2014
FDA Backs Novel First-Line Treatment Pertuzumab for Early Stage Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Monoclonal Antibodies / mAb Tags: breast cancerDocetaxelHER2-positiveHerceptin Sep 18, 2013
The FDA made a historic move on September 12, 2013 with their nod to approve Pertuzumab, a monoclonal antibody (mAb), as a pre-surgical treatment for patients with early-stage metastatic breast cancer. Pertuzumab is currently approved as a treatment for women with late-stage breast cancer, but it is administered after surgery has been completed. This new[…]
FDA Approves Everolimus for Advanced Breast Cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News, Immunosuppressant Tags: 159351-69-6breast cancerEverolimusmetastatic breast cancerPfizer Jul 20, 2012
Novartis gains FDA approval for Afinitor in advanced breast cancer marking a significant milestone for women battling this disease. Everolimus CAS# 159351-69-6, is the active ingredient for Afinitor®. Click for more information on, and availability of Everolimus. Also, click for more articles on breast cancer and the HER2 receptor. The approval was based on a[…]
Is Capecitabine the Next Generic Blockbuster of Chemotherapy Drugs?
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, Compounding API, Drug Research & Development API, Patent Expiration 2015 Tags: breast cancercolorectal cancer Jun 19, 2012
Regarded as a blockbuster drug used to treat both metastatic breast and colorectal cancer, Capecitabine is also known by the trade name Xeloda, which is marketed by Roche Pharamaceuticals. Capecitabine, CAS# 154361-50-9, is waiting in the wings to become a generic boon in the pharmaceutical industry, as the patent for Xeloda meets an expiration in[…]
Denosumab is Poised to be a Boon to Bone Health
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: breast cancermultiple myelomaosteoporosisprostate cancer Mar 14, 2012
Denosumab, CAS number 615258-40-7, offers divergent options for researchers working with this monoclonal antibody. The scope of efficacy for denosumab is wide, with one of it’s uses being an approved treatment of osteoporosis in women, particularly those women who are post menopausal. Known as the brand Prolia®, which is marketed by Amgen, denosumab is effectively[…]
Axitinib Approved for Patients with Advanced Renal Cell Carcinoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: breast cancerhypertensionPfizer Jan 09, 2012
As of December 7, 2011 the Oncologic Drugs Advisory Committee voted to approve Axitinib CAS# 319460-85-0 (Inlyta) as a second-line treatment for patients with Advanced Renal Cell Carcinoma. This unanimous vote was based upon the findings of the phase 3 trial done in 2010, which compared Axitinib and Sorafenib. Axitinib, when compared to Sorafenib in[…]
Epirubicin improves HER2-positive breast cancer survival
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: Anthracyclinesbreast cancercancer treatment Sep 13, 2011
In the recent decades, women’s health has taken center stage. No longer hidden in obscurity, breast cancer emerged as a growing concern for women all over the world. The disease does not just strike women, it affects children and men as well, albeit indirectly. The role of the woman as a mom and earning partner[…]
Toremifene in the prevention and treatment of prostate cancer
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: breast cancerprostate cancer Jun 03, 2011
Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to[…]
Tranilast – Asthma Drug Shows Promise for Treating Breast Cancer
Anti-Asthma / COPD, Chemotherapeutic / Anti-Neoplastic Tags: asthmabreast cancer Dec 03, 2010
LGM Pharma is a US based supplier of the API (Active Pharmaceutical Ingredient) Tranilast CAS# 53902-12-8 for research and development purposes. Tranilast CAS# 53902-12-8 (a drug in current use for treatment of asthma) has performed well in a pre-clinical trial as a potential chemotherapy agent for breast cancer. The drug, tranilast, has been approved since[…]
